NLRC4 and melanoma: Strikingly, the same analysis performed with STING/TMEM173 expression (well-characterized type I IFN signaling mediator) provided much lower coefficient correlations than NLRC4 for those DC2, DC3, and DC4 subsets in both colon and melanoma patient tumors, indicating the role of NLRC4 expression as a critical driver of DC tumor infiltration in multiple cancer types.